STOCK TITAN
  1. Home
  2. News
  3. CALT

Calliditas Therapeutics AB - CALT STOCK NEWS

Welcome to our dedicated news page for Calliditas Therapeutics AB (Ticker: CALT), a resource for investors and traders seeking the latest updates and insights on Calliditas Therapeutics AB.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Calliditas Therapeutics AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Calliditas Therapeutics AB's position in the market.

News
Calliditas Therapeutics appoints Maria Törnsén as President North America
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) appoints Maria Törnsén as President North America, announces full FDA approval of TARPEYO®, and targets top line read out of several Phase 2 clinical trials with setanaxib in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Calliditas to present at JP Morgan Healthcare Conference
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9th, 2024, providing an update on the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) secures 92 million Euro term loan with Athyrium Capital Management, LP, extending debt repayment by 3 years and ensuring continued access to non-dilutive capital. The loan will be used to fully repay the existing 68 million Euro loan with Kreos Capital, with the principal amount of the new loan being 24 million Euros greater than that of the prior facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
News
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
Rhea-AI Summary
Everest Medicines (HKEX 1952.HK) licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) announced that the U.S. FDA has fully approved Nefecon® delayed release capsules for adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Nefecon® demonstrated a significant benefit over placebo in reducing kidney function loss, with a 50% less deterioration in kidney function compared to placebo over a 2-year period. The drug is also approved in China and showed a greater treatment effect in the Chinese subpopulation compared to the global population. Nefecon® is considered a revolutionary therapeutic option for IgAN patients, offering a disease-modifying treatment with sustained and clinically meaningful reduction in eGFR declines and proteinuria. The drug's approval represents a significant milestone for Everest Medicines and its partner Calliditas Therapeutics AB, with plans for a China launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.35%
Tags
none
-
News
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announced FDA approval of TARPEYO (budesonide) to reduce kidney function loss in adults with primary IgAN. TARPEYO is the first fully FDA-approved treatment for IgAN based on a measure of kidney function, showing a 50% reduction in kidney function deterioration in TARPEYO-treated patients compared to placebo-treated patients over a 2-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.35%
Tags
fda approval
-
News
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application covering TARPEYO, strengthening its intellectual property protection and global value proposition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
News
Calliditas announces additions to the management team
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) has announced the addition of a new member to its management team, Head of Technical Operations Lars Stubberud, and the appointment of Brian Gorman as its new Group General Counsel, effective 1 January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
News
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) has initiated a Phase 2 clinical study to evaluate setanaxib in Alport syndrome, a rare genetic disease leading to kidney failure. The study aims to assess the safety, tolerability, and effectiveness of setanaxib in approximately 20 patients with Alport syndrome and significant proteinuria despite treatment with a renin-angiotensin system (RAS) blocker. Dr. Rachel Lennon, the Coordinating Investigator for the study, highlighted the urgent clinical need for treatments that delay the progression to kidney failure in Alport syndrome. Setanaxib is also being evaluated in Phase 2 studies for other conditions like squamous cell carcinoma of the head and neck, primary biliary cholangitis, and idiopathic pulmonary fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
clinical trial
-
News
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) and Everest Medicines (1952.HK) have announced the approval of Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression by China's National Medical Products Administration (NMPA). This approval addresses a significant unmet medical need for novel therapies among IgAN patients in China and other Asian countries, with an estimated five million IgAN patients in China alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
none
News
Calliditas to present at upcoming investor conferences
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) announces participation in several upcoming investor conferences, including the Jefferies London Healthcare Conference and the Stifel Healthcare Conference. CEO Renee Aguiar-Lucander and President of North America, Andrew Udell, will be presenting at these events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
conferences
Stock CALT logo
Calliditas Therapeutics AB

Nasdaq:CALT

CALT Rankings

#2935 Ranked by Market Cap
#1383 Ranked by Stock Gains
N/A Ranked by Dividends

CALT Stock Data

545.72M
37.48M
3.18%
0.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Sweden
Stockholm

About CALT

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.